

09-11-03

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EL 987587502 US Express Mail Label Number 9//a /2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ULRICH POSANSKI

APPLICATION NO: 10/623,887

FILED: JULY 17, 2003

FOR: PHARMACEUTICAL COMPOSITIONS FOR SPARINGLY SOLUBLE

THERAPEUTIC AGENTS

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant wishes to make of record the references cited on attached forms PTO-1449 (8 sheets) which are copied from patent applications 08/578,527, January 5, 1996, abandoned, 09/524,965, March 14, 2000, abandoned, and 10/040,842, January 7, 2002, pending. Since the references are available in said parent applications, copies are not enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 forms.

Respectfully submitted,

Novartis Corporate Intellectual Property One Health Plaza, Building 430 East Hanover, NJ 07936-1080

Gabriel Lope Attorney for Applicant

Reg. No. 28,440

(862) 778-7882

Date: 9/10/03

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. 4-20017/A/PCT

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

SERIAL NO. 08/578,527 1-5-96

GROUP


FOREIGN PATENT DOCUMENTS

XAMINER INITIAL				DOC	UME	NT R			DATE				CLASS	SUBCLASS	TRANSLATION
	AA	0	2	7	4	8	7	0	7-20-88	Europ	<i>ر</i> ي				
	ΑВ	9	3			S		1	12193	PCT					
	AC	2	2	2		1	9	8	8-22-50	Great	e. Britain Britain	٥.			
	ΑD	1	1	1	2	5	1	8	11-6-68	Great	Britain				
	ΑE														
	AF				L	L	L				·				
	AG		L												
	АН			_	L	_		L							
	AI	Ŀ				_	L	L					<u>-</u> -		
	AJ	_	L		L		L	L							
	AK		_		<u> </u>			L							
	AL			_											
	AM							_							
	AN														
	AO														
	АР														
	AQ														
	AR						T								
	AS		T											1	
MAX	VER	L		1		1			L		DATE CONSIDE	RED			1

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION



ATTY. DOCKE 4-20017C APPLICATION NO. Not Yet Known **APPLICANT** ULRICH POSANSKI FILING DATE Herewith

Group 1618

Sheet 1 of 7

U.S. PATENT DOCUMENTS

PAT & IS	ADEMA	SEE SEE	U.S. F	PATENT DOCUMENTS			
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	3,288,824	11/29/66	Mahler, et al.	260	410.6	
	AB	3,813,345	5/28/74	Urton	252	312	
	AC	3,954,967	5/4/76	Urton	424	78	
	AD	4,073,943	2/14/78	Wretlind, et al.	424	358	
	AE	4,146,499	3/27/79	Rosano	252	186	·
	AF	4,156,719	5/29/79	Sezaki, et al.	424	177	
	AG	4,388,307	6/14/83	Cavanak	424	177	
	AH	4,567,161	1/28/86	Posanski, et al.	424	199	
	AI	4,695,450	9/22/87	Bauer, et al.	424	168	
	AJ.	4,719,239	1/12/88	Muller, et al.	514	785	2/22/85
	AK	4,794,000	12/27/88	Ecanow	424	457	1/8/87
	AL	4,797,272	1/10/98	Linn, et al.	424	59	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE ·	CLASS	SUBCLASS	TRAN	SLATION NO
AM	1,171,125	11/19/69	Great Britain	A61K			
AN	1,209,361	8/12/86	Canada	71			
 AO	135,171	3/27/85	Europe (w/abstract)	A61K			
AP	0170,623	2/5/86	Europe	A61K			□·
AQ	256,856	2/24/88	Europe (w/abstract)	A61K			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

-	AR	Abstract of JP 61280435 (1986)
	AS	Cavanak and Sucker, Prog. Allergy Vol. 38:65-72 (1986)
	AT	Remington's Pharmaceutical Sciences (17th ed.). Microemulsions, Chapter 20, pp. 293-300 (1985)

EXAMINER

DATE CONSIDERED

Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

Sheet 2 of 7

FORM PTO-1449 (REV. 7-85)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

sheets if necessary)

ATTY. DOCKET 4-20017C APPLICATION NO. Not Yet Known **APPLICANT ULRICH POSANSKI** FILING DATE Herewith

Group 1618

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	4,797,273	1/10/89	Linn, et al.	424	59	·
	AB	4,798,823	1/17/89	Witzel	514	11	
	AC	4,835,002	5/30/89	Wolf, et al.	426	590	}
	AD	4,888,239	12/19/89	Brox	428	402.2	
-	AE	4,914,188	4/3/90	Dumont, et al.	530	317	
	AF	4,963,367	10/16/90	Ecanow	424	484	
	AG	4,990,337	2/5/91	Kurihara, et al.	424	427	
	АН	4,996,193	2/26/91	Hewitt, et al.	514	11	
	Al	5,037,653	8/6/91	Dawson ·	424	405	
	AJ	5,047,396	9/10/91	Orban, et al.	514	11	7/21/89
	AK	5,154,754	10/13/92	Damo, et al.	71	DIG.1	
	AL	5,342,625	8/1/94	Hauer	424	455	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN	SLATION NO
	. AM	641,356	2/29/84	Switzerland (w/ English abstract)	A61K			
	AN	8,701,035	2/26/87	PCT	A61K			
	AO	8,800,059	1/14/88	PCT	A61K			
	AP	558155	1/28/83	Australia				
	AQ	2 211 408	7/5/89	United Kingdom				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	·
 AR	W.A. Ritschel, Methods and Finding in Experimental and Clinical Pharmacology, Vol. 13, pp. 205-220 (1991)
AS	Reymond, Pharm. Res. Vol. 5, No. 10, pp. 677-679 (1988)
АТ	Ritschel, et al., Meth and Find Exp Clin Pharmacol. Vol. 11(4): 281-87 (1989)

EXAMINER

DATE CONSIDERED

Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

Sheet 3 of 7

FORM PTO-1449 (REV. 7-85)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE.

INFORMATION DISCLOSURE CITATION

if necessary)

ATTY, DOCKET NO. 4-20017C APPLICATION NO. Not Yet Known APPLICANT **ULRICH POSANSKI** FILING DATE Herewith

Group 1618

/	(Use	PE	tal sh	eets
(B	SEP	107	003	EFICE &
B	E.	DRADS	MAEY	7

AL

U.S. PATENT DOCUMENTS EXAMINER INITIAL NAME CLASS SUBCLASS FILING **DOCUMENT NUMBER** DATE DATE 514 11 6/17/97 5,639,724 6/17/97 Cavanak AA 6/11/96 Bollinger, et al. 5,525,590 AB 9 514 5/26/98 AC 5,756,450 Hahn, et al. 4/27/93 Desai AD 5,206,219 9/28/88 8/16/94 Nakajima, et al. **A61K** AE 5,338,761 5/5/98 Asakura et al. AF 5,747,069 424 451 7/31/90 Story et al. 4,944,949 AG 501 Akiyama et al. 424 ΑH 5,576,025 11/19/96 Αl AJ ΑK

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN:	SLATION NO
 AM	9320833	10/28/93	PCT			\boxtimes	
 AN	2,222,770	3/21/90	UK				
 AO	2,228,198	8/22/90	UK				
 AP	2,218,334	11/15/89	UK				
 AQ	2,221,157	1/31/90	UK				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Takada, et al., J. Pharmacobio-Dyn. Vol. 11: 80-87 (1988)
AS	Takada, et al., J. Pharmacobio-Dyn. Vol. 8: 320-323 (1985)
АТ	Takada, et al., J. Pharmacobio-Dyn. Vol. 9: 156-160 (1986)

EXAMINER

DATE CONSIDERED

Initial of reference considered, whether or not citation is in conformance with MPEP 609. Draw a line through citation if not in *EXAMINER: conformance and not considered. Include a copy of this form with the next communication to applicant.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. 4-20017C APPLICATION NO. **ULRICH POSANSKI**

Group 1618

Sheet 4 of 7

Not Yet Known APPLICANT FILING DATE Herewith

SET VENE	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLAS S	TRAN:	SLATION NO
AA	2,642,650	8/10/90	FR (w/abstract)				
AB	2,230,440	10/24/90	UK				
AC	90/08537	8/9/90	PCT				
AD	2,224,205	5/2/90	UK				
AE	4,003,844	8/16/90	Germany (abstract) US 5,	756,	450		
AF	95/22982	8/95	PCT				
AG	96/14079	5/17/96	PCT	·			
AH	3294207	1/25/90	Germany (w/abstract)				
Al	9112008	8/22/91	PCT				
. AJ	0589843	3/30/94	Europe				
AK	2907460	9/13/79	Germany (w/English translatio	n of clain	n 1)		
AL	3930928	3/22/90	Germany (w/abstract)	}			
AM	4005190	8/23/90	Germany (w/abstract)				
AN	365044	4/25/90	Europe				
AO	2257359	1/13/93	United Kingdom <i>EP</i> 53	9,31	9		
AP	295765	11/14/91	Germany (w/abstract)				
AQ	9405312	3/17/94	PCT				
AR	2282586	4/12/95	United Kingdom FP 65	19.6	51		
AS	2278780	12/14/94	United Kingdom				
AT	1375986	12/4/74	United Kingdom				
AU	0010437	4/30/80	Europe				
AV	0139891	5/8/85	Europe			-	
WA	0474126	3/11/92	Europe				
AX	0694308	1/31/96	Europe				
AY	9209299	6/11/92	PCT	1			
AZ	0274870	7/20/88	Europe	1	1		16

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. 4-20017C APPLICATION NO. Not Yet Known APPLICANT ULRICH POSANSKI FILING DATE Herewith

Group 1618

THAT THAT OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.) Yanagawa, et al., J. Microencapsulation 6(2): 161-164 (1989) AA Ritschel, et al., Meth. Find. Clin. Pharmacol., Vol 12, pp. 127-134 (1990) AB The Merck Index, 9th Ed., Merck & Co. Inc., Rahway, N.J. p. 1017 (1976) AC Derwent Abstract of DD298351 (1992) AD Carrigan, et al., J. Pharm. Sci., 1973, Vol. 62, pp. 1476-1479 **AE** Muller, et al., Pharm. Ind. 50(11) 1301-1306 (1988) AF Muller, et al., Pharm. Ind. 50(3): 370-375 (1988) AG Takada et al., Intern'l Journ. of Pharmaceutics, Vol. 44:107-116 (1988) AH Bhargava et al., Pharmaceutical Technology, March 1987 Αl Ekman, S., Lipids 22:657-663 (1987) AJ Ritschel, et al., Pharmaceutical Research Vol. 5(10): Suppl. 108 (1988) AK Frazer, et al., J. Physiol. (1944) Vol. 103, pp. 306-316 AL Takada et al., J. Pharmaceutical Research Vol. 3(1): 48-51 (1986) AM Hahn, Biodegradable Tensides (1988) (translation) AN DATE CONSIDERED **EXAMINER**

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

YUSe several sheets if necessary)

ATTY. DOCKET NO. 4-20017C APPLICATION NO. Not Yet Known **APPLICANT** ULRICH POSANSKI FILING DATE

Group 1618

Sheet 6 of 7

Herewith

TO TRADES	ARRE	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)
	AA	Ziegenmeyer, et al., Acta Pharmaceutical Technologica, Vol. 26(4): 273-275, 1980 (translation)
	AB	Derwent Abstract of FR2678169 (1992)
	AC	Derwent Abstract of FR2553661 (1985)
	AD	Derwent Abstract of WO8602264 (1986)
	AE	Derwent Abstract of DE3315805 (1984)
	AF	Derwent Abstract of JP02004776 (1990)
	AG	Rote Liste 1992, "Sandimmun"
	АН	
	Al	
	AJ	
	AK	
	AL	
	AM	
	AN	
FYAMINER	,	DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

I Puse several sheets if necessary)

ATTY, DOCKET 4-20017C APPLICATION NO. Not Yet Known APPLICANT **ULRICH POSANSKI** FILING DATE Herewith

Group 1618

Sheet 7 of 7

FOREIGN PATENT DOCUMENTS

BADEMAR	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLAS	TRAN	SLATION NO
AA	0274870	7/20/88	Europe		-		
AB	9300891	1/21/93	PCT			1	10
AC	9209299	6/11/92	PCT (w/abstract)			<u> </u>	一
AD	2124259	11/28/94	Canada				
AE	9423733	10/27/94	PCT				
AF	361928	4/4/90	Europe (w/abstract)				
AG	0211258	2/25/87	Europe	· ·			
AH	0274431	7/13/88	Europe				
AI	0315079	5/10/89	Еигоре				
AJ	0314689	5/10/89	Europe				
AK	2098865	12/1/82	Great Britain				
AL	2206119 ·	12/29/88	Great Britain				
AM	2209671	5/24/89	Great Britain				
AN	2211848	7/12/89	Great Britain			10	
AO							
AP							
AQ							
AR			,				
AS							
AT							
AU							
AV							
AW			·				10
AX							ta
AY						吉	1=
AZ	·				 	tā	一
XAMINER	——————————————————————————————————————		DATE CONSIDERED		L	<u> </u>	1

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.